India

India is currently a low-signal country page in Blossom. Blossom does not currently link this page to psychedelic clinical trials, stakeholders, or events, so it should be read as a database placeholder rather than a mature research profile.

Ask Blossom about this country

Data updated May 4, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inIndia.

1
Blossom currently tracks no country-linked psychedelic clinical trials for India.
2
Blossom currently tracks no linked psychedelic stakeholders or events for India.
3
No verified country-specific psychedelic access pathway is recorded in this lightweight page content.
4
Future updates should prioritise verified trial registrations, regulator or health-ministry sources, and locally based organisations before adding more detailed claims.

Research and Access Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to India.

Active trials: 0
Total trials: 1
Stakeholders: 0
Events: 0

Top Compounds

Ketamine(1)

Medical Access

India maintains a restrictive legal regime for classical psychedelics under its national drug-control framework (NDPS Act), so most psilocybin-class, tryptamine, phenethylamine and related compounds have no authorised medical use outside of sanctioned clinical research and are actively policed. Ketamine is widely available and used for anesthesia and is provided off-label in private clinics for psychiatric indications (generally not reimbursed by public insurance); esketamine (Spravato) is not established as a reimbursed or widely marketed therapy in...

View trials→Open access guide→

Regulatory Status

No country-specific psychedelic access review has been completed for India. Readers should not infer legal medical availability, reimbursement, or private clinical access from this placeholder; any access question should be checked compound by compound against current local law and medicines regulation.